Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alessandro Morabito

Showing results (51-60 of 198) with videos related to

Pageof 20
Sort By:
Expert Opinion on Investigational Drugs|November 5, 2010
New drugs in advanced non-small-cell lung cancer: searching for the correct clinical developmentMassimo Di Maio, Alessandro Morabito, Maria Carmela Piccirillo, et al.
Risk Management and Healthcare Policy|July 16, 2021
Risk Analysis in Healthcare Organizations: Methodological Framework and Critical VariablesGiacomo Pascarella, Matteo Rossi, Emma Montella, et al.
Expert Review of Anticancer Therapy|April 9, 2013
Anaplastic lymphoma kinase: a glimmer of hope in lung cancer treatment?Renato Franco, Gaetano Rocco, Federica Zito Marino, et al.
International Journal of Molecular Sciences|September 22, 2017
Angiogenesis Inhibitors in NSCLCAnna Manzo, Agnese Montanino, Guido Carillio, et al.
Multidisciplinary Respiratory Medicine|May 7, 2026
Imaging and AI in tertiary prevention of lung cancer: Narrative review and clinical perspectivesCarlo Molfini Curci, Alessandro Morabito, Raffella Pagliaro, et al.
Current Clinical Pharmacology|July 12, 2018
Second-line Treatment of Advanced Non-small Cell Lung Cancer Non-oncogene Addicted: New Treatment Algorithm in the Era of Novel ImmunotherapyCesare Gridelli, Paolo Antonio Ascierto, Francesco Grossi, et al.
Lung Cancer (Amsterdam, Netherlands)|July 18, 2008
Weekly docetaxel vs. docetaxel-based combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer patients. The DISTAL-2 randomized trialVittorio Gebbia, Cesare Gridelli, Claudio Verusio, et al.
Future Oncology (London, England)|August 29, 2020
Sequential afatinib and osimertinib in patients with <i>EGFR</i> mutation-positive non-small-cell lung cancer: final analysis of the GioTag studyMaximilian J Hochmair, Alessandro Morabito, Desiree Hao, et al.
Analytical Cellular Pathology (Amsterdam)|January 13, 2017
Correlation of Serum Cystatin C with Glomerular Filtration Rate in Patients Receiving Platinum-Based ChemotherapyErnesta Cavalcanti, Vittoria Barchiesi, Dionigio Cerasuolo, et al.
Lung Cancer (Amsterdam, Netherlands)|August 7, 2008
The MILES-2G phase 2 study of single-agent gemcitabine with prolonged constant infusion in advanced non-small cell lung cancer elderly patientsCesare Gridelli, Ermelinda De Maio, Santi Barbera, et al.
Pageof 20

Showing results (51-60 of 198) with videos related to

Sort By:
Pageof 20
Expert Opinion on Investigational Drugs|November 5, 2010
New drugs in advanced non-small-cell lung cancer: searching for the correct clinical developmentMassimo Di Maio, Alessandro Morabito, Maria Carmela Piccirillo, et al.
Risk Management and Healthcare Policy|July 16, 2021
Risk Analysis in Healthcare Organizations: Methodological Framework and Critical VariablesGiacomo Pascarella, Matteo Rossi, Emma Montella, et al.
Expert Review of Anticancer Therapy|April 9, 2013
Anaplastic lymphoma kinase: a glimmer of hope in lung cancer treatment?Renato Franco, Gaetano Rocco, Federica Zito Marino, et al.
International Journal of Molecular Sciences|September 22, 2017
Angiogenesis Inhibitors in NSCLCAnna Manzo, Agnese Montanino, Guido Carillio, et al.
Multidisciplinary Respiratory Medicine|May 7, 2026
Imaging and AI in tertiary prevention of lung cancer: Narrative review and clinical perspectivesCarlo Molfini Curci, Alessandro Morabito, Raffella Pagliaro, et al.
Current Clinical Pharmacology|July 12, 2018
Second-line Treatment of Advanced Non-small Cell Lung Cancer Non-oncogene Addicted: New Treatment Algorithm in the Era of Novel ImmunotherapyCesare Gridelli, Paolo Antonio Ascierto, Francesco Grossi, et al.
Lung Cancer (Amsterdam, Netherlands)|July 18, 2008
Weekly docetaxel vs. docetaxel-based combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer patients. The DISTAL-2 randomized trialVittorio Gebbia, Cesare Gridelli, Claudio Verusio, et al.
Future Oncology (London, England)|August 29, 2020
Sequential afatinib and osimertinib in patients with <i>EGFR</i> mutation-positive non-small-cell lung cancer: final analysis of the GioTag studyMaximilian J Hochmair, Alessandro Morabito, Desiree Hao, et al.
Analytical Cellular Pathology (Amsterdam)|January 13, 2017
Correlation of Serum Cystatin C with Glomerular Filtration Rate in Patients Receiving Platinum-Based ChemotherapyErnesta Cavalcanti, Vittoria Barchiesi, Dionigio Cerasuolo, et al.
Lung Cancer (Amsterdam, Netherlands)|August 7, 2008
The MILES-2G phase 2 study of single-agent gemcitabine with prolonged constant infusion in advanced non-small cell lung cancer elderly patientsCesare Gridelli, Ermelinda De Maio, Santi Barbera, et al.
Pageof 20